The Vienna, Austria company Proxygen GmbH has entered into a multi-year research collaboration and licensing agreement with Merck KGaA to develop molecular glue degrader therapies. This is the second collaboration involving molecular glue agents to be negotiated in recent weeks. In May, Bristol Myers Squibb Co extended a drug discovery partnership with Evotec SE to include molecular glue degraders.
